Clindamycin Resistance

The rising level of clindamycin resistance in skin and soft tissue infections is generating increasing concern in the healthcare community. As the lines between community and hospital-acquired strains S. aureus continue to blur, clinicians need a diagnostic platform that is capable of assessing patients for clindamycin susceptibility or resistance in skin and soft tissue infections.

MicroPhage proposes to have the first product to rapidly identify these strains through our easy-to-use bacteriophage amplification platform. Designed to work in parallel with the KeyPath^™ MRSA/MSSA Skin and Soft Tissue Test, the KeyPath Clindamycin Test will enable clinicians to rapidly and directly determine if a known S. aureus is susceptible or resistant to clindamycin.

By providing definitive identification faster than standard diagnostic methods, as well as critical antibiotic susceptibility and resistance information, the MicroPhage test will enable physicians to prescribe the most effective treatment early in the course of the disease.